Cambridge, MA — February 6, 2017 — Aura Biosciences, a biotechnology company
developing a new class of therapies to target and selectively destroy cancer cells using viral nanoparticle conjugates, announced today that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug application (IND) for the company's lead program, light - activated AU - 011 in
ocular melanoma (OM).
Cambridge, MA — March 30, 2017 — Aura Biosciences, a biotechnology company
developing a new class of therapies to target and selectively destroy cancer cells using viral nanoparticle conjugates, announced today that it has enrolled and dosed the first patient in its Phase 1b clinical trial of light - activated AU - 011, an investigational, first - in - class targeted therapy in development for the treatment of
ocular melanoma, a rare and life - threatening disease.